




Dr. Juan José Infante

CEO



Vaxdyn Objective

Take advanced biotechnology to the front of the **fight against** antibiotic-resistant bacteria.


Vaxdyn Mission

International reference for development of **biologicals** against infections caused by multi-drug resistant bacteria.

Business Strategy

LONG-TERM: PRODUCTS

development of
antigens/immunomodulators/nanoparticles/mAbs



Products


Vaxdyn pipeline					
Therapeutic Area	Product Candidate	Discovery	Preclinical	Phase I	Phase II
Year of completion		2013	2014	2015	2016
<i>Acinetobacter baumannii</i>	VXD-001 (vaccine)				
Year of completion		2014	2015	2016	2017
<i>Pseudomonas aeruginosa</i>	VXD-002 (vaccine)				
<i>Acinetobacter baumannii</i>	VXD-003 (mAb)				

Business Strategy

SHORT-TERM: SERVICES

discovery/performance of
antigens/immunomodulators/nanoparticles/mAbs

- **VaxDefine** discovery platform for the rapid and cost-effective identification of antigens with a high probability of success. Expertise in immunomodulatory modules.
- Expertise in animal models of infection with multidrug-resistant bacterial pathogens for proof-of-concept testing.
- Large collections of epidemiologically diverse bacterial pathogens for molecular epidemiology studies of identified antigens.




Target: *Acinetobacter*
Scope: monoclonal
Partner (L°): USA

Target: *Pseudomonas*
Scope: monoclonal
Partner (L°): China

Target: *Klebsiella*
Scope: vaccine
Partner (L°): Russia

Target: *Acinetobacter*
Scope: vaccine
Partner (L°): France



Market

Traditional
Emerging

Strategic
Partnerships




Virgen del Rocío
Hospital
(+Network)
IBiS



Patients
Strains
Facilities
PhDs/MDs
Strategies

The future:





Juanjo Infante, Ph.D.

Chief Executive Officer

juanjo.infante@vaxdyn.com

Hospital Universitario Virgen del Rocío

Edif. Laboratorios, 1º Plt. Despacho 3

Avda. Manuel Siurot, s/n 41013

Sevilla (Spain)

Phone: (34) 606660701

Web: www.vaxdyn.com

